Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck. (4th May 2021)

• Record Type: Journal Article
• Authors: Leung, Henry WC; Lang, Hui-Chu; Wang, Shyh-Yau; Leung, John Hang; Chan, Agnes LF
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 21:Number 3(2021)
• Page Start: 489
• Page End: 495
• Publication Date: 2021-05-04
• Subjects: Cost-utility analysis -- net monetary benefit -- stereotactic body radiation therapy -- cetuximab -- squamous cell carcinoma of the head and neck; Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1080/14737167.2021.1890585
• Languages: English
• ISSNs: 1473-7167

Abstract

ABSTRACT: Background: This study aimed to estimate the cost-utility of stereotactic body radiotherapy (SBRT) plus cetuximab for patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Methods: We constructed a Markov health-state transition model to simulate costs and clinical outcomes of recurrent squamous cell carcinoma of the head and neck. Model parameters were derived from the published literature and the National Health Insurance Administration reimbursement price list. Incremental cost-effectiveness ratio and the net monetary benefit were calculated from a health payer perspective. The impact of uncertainty was modeled with one-way and probabilistic sensitivity analyses. Results: In the base-case, SBRT plus cetuximab compared to SBRT alone resulted in an ICER of NT$ 840, 455 per QALY gained. In the one-way sensitivity analysis, the utility of progression-free state for patients treated with SBRT plus cetuximab or SBRT alone and the cost of progression-free survival for SBRT+Cet were the most sensitive parameters in the model. Probabilistic sensitivity analysis showed that the probability of cost-effectiveness at a willingness-to-pay threshold of NT$ 2, 252, 340 per QALY was 100% for SBRT plus cetuximab but 0% for SBRT alone. Conclusions: This study showed that SBRT+Cet was cost-effective and benefited patients with previously irradiated rSCCHN.